Phase II Study of Docetaxel and Thalidomide as a Second-Line Treatment for Non-Small Cell Lung Cancer.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Docetaxel; Thalidomide
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 01 Feb 2010 Biomarkers information updated
- 09 Jun 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 27 Dec 2007 The expected completion date for this trial is now 1 Oct 2007.